CME

Host: Guy Young, MD

Guest: Annette von Drygalski, MD, PharmD, RMSK

Guest: Steven Pipe, MD

Guest: Robert Sidonio Jr, MD, MSc

Despite major advances in prophylaxis and supportive care, hemophilia continues to disrupt daily life, limit function, and compromise long-term well-being for many patients. Joint bleeding, subclinical bleeding, and progressive arthropathy remain important concerns, even in the modern treatment era, with ongoing impacts on pain, mobility, and health-related quality of life. Clinicians must keep pace with shifting treatment strategies, including updated factor VIII (FVIII) target levels from recent guidelines to mediate bleeding protection and the growing role of rebalancing agents. To deliver optimal care, healthcare professionals need a clearer understanding of how to preserve joint health across the lifespan, apply evolving treatment targets judiciously, and select and integrate therapies in ways that reflect the latest clinical evidence, patient priorities, and treatment burden. This activity addresses these needs through expert-led discussions focused on long-term joint outcomes, FVIII-targeted treatment strategies, and the practical clinical integration of rebalancing agents.

Faculty: Cem Akin, MD, PhD

This online CME activity explores the clinical complexity and real-world impact of systemic mastocytosis through both clinician insight and patient experience. Participants will examine the multisystem burden of this disease, challenges in diagnosis, and the importance of recognizing symptoms that are often underestimated. The program reviews current evidence-based and targeted treatment strategies to support personalized care across clinical settings. Faculty also goes in-depth on shared decision-making and integrating patient perspectives into management plans. Multidisciplinary approaches to monitoring treatment response, managing adverse events, and sustaining quality of life are also highlighted.

Faculty: Harry Erba, MD, PhD

This educational series explores evolving strategies in the management of acute myeloid leukemia (AML) with a focus on targeted therapies. Faculty experts will review molecular diagnostics and guideline-driven use of FLT3 and menin inhibitors across treatment lines, including frontline, relapsed/refractory, and maintenance settings. Participants will examine clinical trial data, adverse event management, and practical applications through real-world case discussions. The activity emphasizes evidence-based sequencing, MRD assessment, and safety monitoring to support optimal patient outcomes.

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Guest: Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert

Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC

Guest: Pam R. Taub, MD, FACC, FASPC

On-demand webcast covering the latest advances in lipid management and atherosclerotic cardiovascular disease risk reduction, including the emerging role of lipoprotein(a), data on novel lipid-lowering therapies, and strategies for individualizing care for patients with hyperlipidemia.

Faculty: Deepak Sambhara, MD

This rebroadcast of a live regional meeting series, part of The Focused Sight Initiative: Quality Improvement Interventions in Retinal Diseases, brings together retina specialists and eye care professionals to address systemic gaps in the timely diagnosis, referral, and management of patients with retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). Faculty discuss the clinical consequences of treatment delays, highlight real-world challenges to intravitreal anti-VEGF therapy adherence, and examine disparities in access to care. Learners will explore best practices for identifying patients at risk for progression, optimizing referrals from optometry to retina specialists, and implementing patient-centered communication strategies to improve outcomes. Emphasis is placed on leveraging imaging tools for earlier detection, addressing cultural and socioeconomic barriers, and adopting practice-level interventions to reduce loss to follow-up.

Host: Leandra A. Barnes, MD

Guest: Mikael Horissian, MD, MBA

Guest: Katrina H. Lee, MD

Guest: Venessa Peña-Robichaux, MD

On-demand webcast on the pathophysiology of hidradenitis suppurativa (HS), best practices for its timely diagnosis and long-term management, and the latest data on emerging therapies.

Faculty: John E. Anderson, MD

Faculty: Davida F. Kruger, CNP

Continuous glucose monitoring (CGM) has been widely used in individuals with type 1 diabetes (T1D), and evolving guidelines increasingly recommend its use for those with type 2 diabetes (T2D) as well. However, despite these updated recommendations, real-world adoption to support T2D management has remained lower than expected. Before exploring how to apply CGM in practice, let’s first review the benefits and supporting evidence.

Faculty: Richard Lafayette, MD, FACP

Faculty: Ankana Daga, MD

Complement-mediated kidney diseases such as C3 glomerulopathy (C3G) continue to present significant diagnostic and therapeutic challenges in nephrology for both adult and pediatric patients. Among children, this rare disease can progress to end-stage kidney disease within 10 years of diagnosis. Traditional treatment options include supportive care and immunotherapies, but both approaches are only modestly effective in reducing proteinuria. The approval of complement inhibitors, particularly those directed to C3, is a major treatment advance for C3G, revolutionizing the care of patients in this setting. In this activity, experts in the field of nephrology review the clinical evidence for these therapies and offer practical tips regarding their optimal use in pediatric patients.

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Guest: Stephen J. Greene, MD, FACC, FHFSA

Guest: Anne Louise Peters, MD

On-demand webcast on best practices for optimizing guideline-directed medical therapy in cardiovascular-renal-metabolic (CRM) care and employing SGLT2 inhibitors to treat patients with CRM conditions, including heart failure.

Faculty: Antoine Lanot, MD, PhD

Faculty: Gil Yosipovitch, MD

Despite effective and recommended therapies, many healthcare providers still consider antihistamines as the first-choice treatment for CKD-associated pruritus. Join Drs. Antoine Lanot and Gil Yosipovitch as they review a clinical patient case from a multidisciplinary perspective and consider best practices for the diagnosis, treatment, and management of CKD-aP.